New Blood Test Markers Could Help Predict Who Benefits From Experimental LADA Treatment

Latent autoimmune diabetes in adults (LADA) occupies an unusual middle ground. It shares features with both Type 1 diabetes—an autoimmune condition where the body attacks insulin-producing cells—and Type 2 diabetes, which involves insulin resistance. Despite being more prevalent than Type 1 diabetes, LADA remains understudied and is frequently misdiagnosed as Type 2 diabetes.

The challenge for patients and doctors alike is that LADA develops slowly and unpredictably. Predicting which treatments will work for which patients remains a major gap in diabetes care. A new study suggests a way to bridge that gap.

Researchers developed a mouse model of LADA and tested a combination treatment (CT) consisting of three existing drugs: GABA, sitagliptin, and omeprazole. The results were striking: approximately 30% of treated mice achieved normal blood sugar levels and became independent of insulin injections—a sign of therapeutic response that researchers termed 'recovery.'

While 30% may seem modest, it represents a significant finding in a disease that currently has no proven cure. The discovery opens questions about why some patients respond while others do not, and whether the same treatment approach could work in humans.

The most promising aspect of this research is the identification of two cell-free RNA markers—Adgrb1 and Chd5—that distinguished treatment responders from non-responders in the mouse model. Cell-free RNA refers to genetic material circulating in the blood that can be detected with a simple blood test.

If these markers prove reliable in human studies, they could enable doctors to identify which LADA patients are likely to benefit from combination treatment before starting therapy. This precision medicine approach could spare patients from unnecessary treatment while directing resources toward those most likely to benefit.

The researchers observed that successful treatment involved the growth of new insulin-producing beta cells—a process called beta-cell neogenesis. In mice that achieved remission, the immune system's inflammatory response (insulitis) shifted. Specifically, the immune cells present were primarily T regulatory Type 1 cells, which are thought to suppress harmful autoimmunity rather than promote it.

This immune shift may create an environment where beta cells can survive and regenerate. The findings offer clues about how combination therapy might work, though the specific roles of each drug—GABA, sitagliptin, and omeprazole—remain to be fully understood.

This research represents important progress in understanding LADA, but it is based entirely on mouse models. Findings in mice do not always translate to humans. No human clinical trials of this specific combination treatment have been reported.

The study does not change current treatment recommendations for LADA patients. However, it identifies promising directions for future research and may eventually inform the development of personalized diagnostic tools. Anyone with LADA should continue working with their healthcare team on evidence-based management strategies while staying informed about emerging research.

Source: MedComm. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.